Thus, in the trigeminal ganglion, the MAGL/2-AG axis is a highly tunable target for pharmacological interventions aiming to reduce peripheral mechanisms of migraine pain through enhanced level of endoCBs. This evidence concerns the gene MGLL and migraine disorder.